Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study

NCT04252742 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04252742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04252742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
September 15, 2020
Completion date
October 26, 2023
Enrollment
512 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

migraine